文献速递药物不良反应与药物警戒

新冠疫苗接种后吉兰-巴雷综合征:突尼斯病例系列

Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
PubMed 文献 · Br J Clin Pharmacol · 2022-11-29

该研究为突尼斯国家药物警戒中心2021年3月至2022年5月收集的新冠疫苗接种后吉兰-巴雷综合征(GBS)病例的回顾性描述性研究,共纳入4例(9例中5例因信息不足排除)。男性占75%(3/4),最常见疫苗为ChAdOx1 nCoV-19(2例,50%),接种至症状发作平均间隔15.3天,所有患者均接受5天静脉注射免疫球蛋白治疗,3例临床改善,1例(25%)出现治疗相关波动。观察提示新冠疫苗可能与GBS相关,需持续监测和进一步研究。

要点

  • 新冠疫苗接种后GBS罕见,本研究仅纳入4例,男性占75%。
  • 接种至症状发作平均间隔15.3天,临床表现包括经典型和单侧面瘫型。
  • 所有患者接受5天IVIG治疗,3例改善,1例出现治疗相关波动。

核心结论

  • 观察提示新冠疫苗可能与吉兰-巴雷综合征相关,但需持续监测和进一步研究评估关联意义。

研究设计与样本

  • 突尼斯国家药物警戒中心2021年3月至2022年5月收集的新冠疫苗接种后GBS病例的回顾性描述性研究,9例报告中4例纳入分析。

主要发现

  • 纳入4例,男性占75%(3/4);ChAdOx1 nCoV-19疫苗2例(50%),Ad26.COV2.S和BNT162b2各1例。
  • 接种至症状发作平均间隔15.3天;经典型GBS 2例,单侧面瘫型GBS 2例。
  • 所有患者接受5天静脉注射免疫球蛋白治疗,3例临床改善,1例(25%)出现治疗相关波动。

临床怎么用

  • 临床药师应关注新冠疫苗接种后GBS的罕见信号,协助识别接种后新发神经系统症状并及时报告药物警戒系统。

局限性

  • 9例中5例因信息不足被排除,最终仅分析4例,样本量小。
  • 回顾性描述性研究,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the COVID-19 vaccination campaign progresses worldwide, Guillain-Barré syndrome (GBS) vaccine-related cases have been reported. We carried out a retrospective, descriptive study of GBS patients following COVID-19 vaccine, submitted to the National Pharmacovigilance Center of Tunis during the period between March 2021 and May 2022. Our study aimed to identify epidemiological and clinical features of COVID-19 vaccine-associated GBS. We found 9 cases of GBS post COVID-19 vaccination; 5 of them were excluded due to the lack of information, whereas 4 cases were included in this study. Men represented 75% (3/4) of the cases. The most frequently reported vaccine type was ChAdOx1 nCoV-19 vaccine (n = 2 reports [50%]), Ad26.COV2.S vaccine and BNT162b2 vaccine in 1. The mean time interval from vaccination to symptom onset was 15.3 days. Clinical manifestations were different: classical GBS in two cases and GBS with unilateral facial palsy in the other 2 cases. All patients were treated with a course of intravenous immunoglobulin for 5 days. Three patients reported clinical improvement while one case (25%) showed treatment-related fluctuations. Our observations suggest that COVID-19 vaccines may be associated with GBS. Continuous surveillance and further studies are warranted to assess the significance of the association.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Berrim K, Lakhoua G, Zaiem A, et al. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series. Br J Clin Pharmacol. 2022. PMID: 36398559. doi:10.1111/bcp.15601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。